Related Experiment Videos
Immunotherapy with transfer factor of recurrent herpes simplex type I
S Estrada-Parra1, R Chávez-Sánchez, R Ondarza-Aguilera
1Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, México, D.F.
Archives of Medical Research
|January 1, 1995
Summary
Transfer Factor (TF) significantly reduced herpes simplex type 1 recurrence frequency and acute phase duration in a clinical trial. This immunomodulator shows promise as a primary treatment for HSV-1, offering improved patient outcomes.
Area of Science:
- Immunology
- Virology
- Clinical Medicine
Background:
- Herpes simplex type 1 (HSV-1) infections cause recurrent, debilitating outbreaks.
- Existing treatments, including acyclovir, have limitations in managing HSV-1 frequency and duration.
- Immunomodulatory therapies offer a potential alternative for managing recurrent HSV-1.
Purpose of the Study:
- To evaluate the efficacy of Transfer Factor (TF) in treating recurrent herpes simplex type 1.
- To assess TF's impact on the duration of acute phases and the frequency of relapses.
- To compare TF treatment outcomes against previous therapies in a patient self-controlled study.
Main Methods:
- A clinical trial involving 20 patients with a history of recurrent HSV-1.
- Patients served as their own controls, comparing TF treatment to prior therapies.
- TF was administered subcutaneously during acute phases and as maintenance therapy for 6 months.
- Statistical analysis using Student's t-test and Mann-Whitney U test was performed.
Main Results:
- TF treatment resulted in a statistically significant reduction in HSV-1 recurrence frequency (p=0.0001).
- The average duration of the acute phase of HSV-1 was significantly reduced with TF treatment (p=0.0005).
- Six out of 20 patients experienced recurrence during maintenance, managed with initial dosage schedules.
Conclusions:
- Transfer Factor (TF) is an effective immunomodulator for treating herpes simplex type 1.
- TF significantly improves outcomes by reducing both the frequency and duration of HSV-1 recurrences.
- TF represents a potential therapeutic agent of choice for managing HSV-1 disease.